OBSOLETE: Rejection after corneal transplantation Advocacy Hub | UniteRare

At a Glance

Live from database

💊

1FDA treatments

📰

1Recent news

Regulatory Watchboard

No FDA or trial events recorded yet for OBSOLETE: Rejection after corneal transplantation.

Financial Assistance

FINANCIAL LANDSCAPE SUMMARY

Total programs

No financial assistance programs currently listed for OBSOLETE: Rejection after corneal transplantation.
Check the disease page for updates →

Approved Treatments

1 FDA-approved

Astagraf XL

(tacrolimus extended-release capsules)Orphan drugstandard

Astellas Pharma Global Development, Inc.

12.1 Mechanism of Action Tacrolimus binds to an intracellular protein, FKBP-12. A complex of tacrolimus-FKBP-12, calcium, calmodulin, and calcineurin ...

FDA label ↗

View full treatment details on disease page →

Clinical Trial Landscape

No active clinical trials currently recruiting for OBSOLETE: Rejection after corneal transplantation.
Search all trials →

Search clinical trials for OBSOLETE: Rejection after corneal transplantation →

Recent News & Research

1 article

BREAKINGFDA

FDA Approves MYCOPHENOLATE MOFETIL

MYCOPHENOLATE MOFETIL (MYCOPHENOLATE MOFETIL) received FDA approval.

Read ↗

Browse all OBSOLETE: Rejection after corneal transplantation news →

Specialist Network

No specialists currently listed for OBSOLETE: Rejection after corneal transplantation.

View all OBSOLETE: Rejection after corneal transplantation specialists →

Quick Actions

📄

View Disease Page

Full profile, treatments, community

🔬

Search Clinical Trials

Find recruiting studies now

🩺

Find Specialists

Ranked by expertise & trials

💰

Financial Assistance

Copay cards, PAPs, grants

📰